The University of Texas MD Anderson Cancer Center
Camilo Jimenez is a Professor of Oncological Endocrinology at the University of Texas MD Anderson Cancer Center. Dr. Jimenez is the head of the Pheochromocytoma and Paraganglioma research group. This group tries to identify effective therapies for patients with pheochromocytomas and paragangliomas. Dr. Jimenez is the principal investigator of several phase 2 clinical trials for patients with metastatic pheochromocytomas and paragangliomas. One of these clinical trials led to the approval of the high specific activity MIBG for the treatment of patients with unresectable/malignant pheochromocytomas and paragangliomas by the United States Food and Drug Administration in 2018. Dr. Jimenez was the Chair of the International Society for Pheochromocytoma and Paraganglioma Research (PRESSOR) from 2011 through 2014. Dr. Jimenez has published more than 100 peer reviewed manuscripts in the field of Oncological Endocrinology.
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Friday, May 8, 2020
2:10 PM – 2:50 PM